Related Experiment Videos
Blood pressure control and benefits of antihypertensive therapy: does it make a difference which agents we use?
1Unidad de Hipertensión, Hospital 12 de Octubre, Madrid, Spain. Luis_M_Ruilope@teleline.es
Insights
Antihypertensive therapy lowers blood pressure, reducing stroke and heart failure risks. However, whether some drugs offer benefits beyond blood pressure reduction remains uncertain, despite evidence of vascular improvements.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Antihypertensive therapy significantly reduces risks of stroke, heart failure, and renal failure in hypertensive patients.
- High blood pressure poses a substantial risk, particularly in milder forms of hypertension, affecting a large patient population.
- Blood pressure reduction provides less protection against coronary heart disease compared to stroke.
Purpose of the Study:
- To debate whether blood pressure lowering alone explains the benefits of antihypertensive therapy.
- To investigate if specific antihypertensive agents offer advantages beyond their pressure-lowering effects.
- To evaluate evidence for drug-specific properties influencing outcomes in hypertension management.
Main Methods:
- Review of multicenter randomized clinical trials involving various antihypertensive agents.
- Analysis of mechanistic studies on drug effects on vascular remodeling and endothelial function.
- Comparison of findings from mechanistic studies with outcomes from clinical trials.
Main Results:
- Established efficacy of blood pressure lowering in reducing major adverse cardiovascular events.
- Emerging evidence suggests certain agents, like renin-angiotensin system inhibitors and calcium channel blockers, may correct vascular dysfunction.
- Difficulty in extrapolating mechanistic findings to hard clinical endpoints and vice versa.
Conclusions:
- The extent to which antihypertensive benefits are solely due to blood pressure reduction is debated.
- While some drugs may have unique properties beneficial beyond blood pressure lowering, conclusive evidence from outcome trials is limited.
- The question of whether specific antihypertensive agents offer benefits beyond blood pressure reduction remains largely unanswered.
Abstract:
This article debates the important question of whether blood pressure lowering alone is responsible for the benefits accrued from antihypertensive therapy as demonstrated in many multicenter randomized clinical trials with different antihypertensive agents or whether there is evidence that some agents have special properties that result in benefits that go beyond those resulting from lowering blood pressure. Over the past >/=30 years, it has been demonstrated beyond any doubt that lowering blood pressure in severe forms of hypertension, and more recently in systolic and even mild hypertension, will result in reduced incidence of stroke and slower progression of heart and renal failure. These effects have been easier to demonstrate in sicker patients, because enough end points may be counted in the 3 to 5 years that these clinical trials last. However, risk attributable to high blood pressure comes, to a greater degree, from the much larger group of hypertensive individuals who have less severe forms of hypertension. Blood pressure lowering offers less protection from coronary heart disease, which is highly prevalent in hypertensive patients, than from stroke. With the introduction of agents such as renin-angiotensin system inhibitors or calcium channel blockers, it has been demonstrated that hypertensive vascular remodeling and endothelial dysfunction may be corrected. It has therefore been suggested that benefits beyond blood pressure lowering may be achieved with the use of specific drugs to lower blood pressure. Although some evidence suggests that this may be the case, it is difficult to extrapolate from mechanistic studies to prevention of hard end points in outcome trials and vice versa. The question remains for the time being largely unanswered.